Concepedia

Anne Keating

AK

Statistics

Publications

16

Citations

1.1K

H-Index

15

Active since

2002

Affiliations

Astellas Pharma (United States)(Current)

Sidney Kimmel Comprehensive Cancer Center

Astellas Pharma (Japan)

Georgetown University

Dana-Farber Cancer Institute

Anne Keating is an author at Astellas Pharma (United States) specializing in pharmacology, medicine, and cancer pharmacology.

Publications per year

2002–2017

16

Publications

16

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

Anthony W. Tolcher, Alain C. Mita, Lionel D. Lewis et al. · Journal of Clinical Oncology · 2008 · 239 citations · Full text

, , +17

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer

Ronan J. Kelly, Anish Thomas, Arun Rajan et al. · Annals of Oncology · 2013 · 172 citations · Full text

, , +17

A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer

A. W. Tolcher, David I. Quinn, Anna C. Ferrari et al. · Annals of Oncology · 2011 · 160 citations

, , +15

A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B‐cell lymphoma

Bruce D. Cheson, Nancy L. Bartlett, Julie M. Vose et al. · Cancer · 2011 · 126 citations · Full text

, , +15

Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer

Michael Clemens, Oleg Gladkov, Elaina M. Gartner et al. · Breast Cancer Research and Treatment · 2014 · 79 citations · Full text

, , +17

1–5 of 16